BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//BioCatalystFeed//bcf//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:BioCatalystFeed GOVX catalysts
X-WR-CALDESC:Scheduling/reference data from public records\; dates can move
 . Not investment\, legal or medical advice.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:2620e66cb4c2fda35df5@biocat.ai
DTSTAMP:20261118T181353Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:GOVX P2 readout (est.): SARS-CoV-2 Vaccine (GEO-CM04S1) Versus mRNA
  SARS-COV-2 Vaccine in Patients With Blood Cancer
DESCRIPTION:SARS-CoV-2 Vaccine (GEO-CM04S1) Versus mRNA SARS-COV-2 Vaccine 
 in Patients With Blood Cancer\nNCT04977024 | PHASE2 | ACTIVE_NOT_RECRUITIN
 G | sponsor: GeoVax\, Inc.\nPrimary completion date (ESTIMATED)\; top-line
  results usually follow later.\nTicker GOVX (confidence 0.6)\nSource: http
 s://clinicaltrials.gov/study/NCT04977024\nScheduling/reference data from p
 ublic records\; dates can move. Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT04977024
CATEGORIES:readout,ESTIMATED
END:VEVENT
END:VCALENDAR
